Published 2011-01-01
Yudi Y Ambeng Sabilal Alif Doddy M Soebadi


Objective: To study the relationship between obesity, prostate specific antigen (PSA) level, and prostate volume in patients with benign prostate hyperplasia (BPH) without urinary retention.Material & Method: Twenty two BPH patients without urinary retention were enrolled in this study. Patients were classified into 2 groups based on body mass index (BMI). The first group consisted of 11 patients with obesity (BMI ≥ 27 kg/m2), the second group consisted of 11 non obese patients (BMI <  27 kg/m2). Each patient underwent measurement of PSA, prostate  volume and hematocrit. We performed tests for correlation between all variables in both groups. Results: From correlation testing there was a significant relationship between obesity and PSA. With increasing BMI, a lower PSA level was observed (p< 0,05). There was no significant relationship between prostate volume and hematocrit (p > 0,05).Conclusion: There is a significant negative correlation between obesity and PSA in BPH patients without urinary retention



Ostman J, Britton M, Jonsson E. Treating and preventing obesity; 2004.

Lee S, Hong GM, Sang HC, Yun JK, Sang WO, Young

JK, et al. Central obesity as a risk factor for prostatic hyperplasia. Obesity A Research Journal 2006; 14:172-9

Lionel LB, Partin AW, Robert JM, Robin TV, Leon S, Carmen R, et al. Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. JAMA 2007; 298 (19): 2275-80

Choi NG, Kim HJ, Shin TS. Relationship between prostate-specific antigen and obesity in Korea. Eur Urol Suppl 2006: 5 (2): 316

In Ho Chang, Seung HA, June HH, Tae-Hyoung K, Young SK, Soon CH. The clinical significance in healthy men of the association between obesity related plasma hemodilution and tumor marker concentration. J Urol 2009; 181: 567-73.

Kazuhiro O, Endo F, Muraishi O, Hiramatsu S, Yano E.

Relationship between prostate-specific antigen and hematocrit: Does hemodilution lead to lower PSA concentrations in men with a higher body mass index? Urology 2010; 75 (3): 652-3.

Parsons JK, Ballentine C, Alan WP, Gwen W, Jeffrey M, Luigi F, et al. Metabolic factors associated with benign prostatic hyperplasia. J Clin Endocrinol Metab 2006; 91: 2562-8.

Xieab Li-Ping, Yu Baia, Xin-Zong Z, Xiang-Yi Z, Ling Xub. Obesity and benign prostatic enlargement: A large observational study in China. J Urol 2007; 69: 680-4

Stephen BF, Platz EA, Presti BC Jr, Arohson WB, Amling CL, Biare C, et al. Obesity, serum prostate specific antigen and prostate size: Implications for prostate cancer detection. J Urol 2006; 75 (123): 500-4

Meigs JB, Mohr B, Barry MJ, Collins MM, McKinley JB. Risk factor for clinical benign prostatic hyperplasia in a community-based population of healthy aging men. J Clin Epidemiol 2001; 54: 935-44.

Loeb S, Yu X, Nadler RB, Roehl KA, Han M, Hawkins SA, et al. Does body mass index affect preoperative prostate specific antigen velocity or pathological outcomes after radical prostatectomy? J Urol 2007;177: 102-6.

Hendra Sutapa, Wahjoe Djatisoesanto, Doddy M. Soebadi. Pengukuran volume prostat pasien BPH menggunakan colok dubur dan USG transrektal dengan operator yang sama dibandingkan dengan pengukuran volume prostat menggunakan TAUS dengan operator berbeda. JURI 2007; 14 (2): 34-9

January 2011 Vol. 18 No. 1
Copyright Information
Department of Urology, Faculty of Medicine/Airlangga University